Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart failure continues to be unacceptably high. No intervention in 2 decades has been shown to improve this risk.

In this interview, Javed Butler, MD, MPH, MBA, and Sun Moon Kim, MD, FACC, discuss the results of the EMPACT-MI trial.

Related References:

1. Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Andersen, K. R., Sumin, M., Zwiener, I., Hernandez, A. F., & Butler, J. (2023). Baseline characteristics of patients enrolled in the EMPACT-MI trial. European journal of heart failure, 25(9), 1708–1715. https://doi.org/10.1002/ejhf.2990
2. Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Vedin, O., Sumin, M., Zwiener, I., Hernandez, A. F., & Butler, J. (2022). Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American heart journal, 253, 86–98. https://doi.org/10.1016/j.ahj.2022.05.010